RARE DISEASERESEARCH ATLAS

ORPHA:52503

X-linked creatine transporter deficiency

low confidenceDisorder

Also known as: Creatine transporter deficiency · SLC6A8 deficiency

Publications

1,844

Trials

3

Interventional, condition-specific

Researchers

1,182

Distinct authors in sample

Gene link

SLC6A8

Definitive

Readiness

6/6

Stages with a signal

Clinical definition (Orphanet)

X-linked creatine transporter deficiency (CRTR-D) is a creatine deficiency syndrome characterized clinically by global / (DD/ID) with prominent speech/language delay, autistic behavior and .

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

cerebral creatine deficiency syndrome 1 · cerebral creatine deficiency syndrome 1, X-linked recessive · cerebral creatine deficiency syndrome type 1 · creatine transporter deficiency

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

6/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Definitive — SLC6A8

  2. LiteraturePresent

    1,844 matched papers (1,275 in last 10 years) Source

  3. Phenotype characterisedPresent

    73 HPO annotations (e.g. Ptosis; Self-mutilation; Intellectual disability) Source

  4. Animal modelPresent

    5 genotype models (Mus musculus) Source

  5. Orphan designationPresent

    1 FDA designation (1 FDA orphan-indication approval) — e.g. cyclocreatine Source

  6. Interventional trialPresent

    3 matched on ClinicalTrials.gov (2 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (SLC6A8).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

73

Associated phenotypes · MONDO:0010305

  • Ptosis
  • Self-mutilation
  • Intellectual disability
  • Seizure
  • Hypertonia

Showing 5 of 73 — open Monarch for the full list.

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

1

Designation · 1 with FDA orphan-indication approval

  • FDA cyclocreatineCreatine transporter deficiency · 2012-06-18 · Not FDA Approved for Orphan Indication

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

1 associated chemical · 4 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Creatine · marker/mechanism

Pathways: Metabolism; Metabolism of polyamines; Creatine metabolism; Metabolism of amino acids and derivatives

MyDisease.info · MONDO:0010305

Literature

Is anyone studying this?

1,844

1,844 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,844 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,275 in the last 10 years · low confidence

Phrase hits: 593 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,182

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Salomons GS14 papers · 2025

    Metabolic Unit, Department of Clinical Chemistry, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands.

    Papers in Europe PMC
  2. 02
    Baroncelli L13 papers · 2026

    Department of Developmental Neuroscience, IRCCS Stella Maris Foundation, I-56128 Pisa, Italy.

    Papers in Europe PMC
  3. 03
    Putignano E12 papers · 2026

    Institute of Neuroscience, National Research Council (CNR), Via Moruzzi 1, 56124, Pisa, Italy.

    Papers in Europe PMC
  4. 04
    Porter FD11 papers · 2026

    Section on Molecular Dysmorphology, Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA. Electronic address: fdporter@mail.nih.gov.

    Papers in Europe PMC
  5. 05
    Mabondzo A10 papers · 2025

    Service de Pharmacologie et d'Immunoanalyse, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France.

    Papers in Europe PMC
  6. 06
    Skelton MR10 papers · 2026

    Department of Pediatrics, University of Cincinnati College of Medicine & Division of Neurology, Cincinnati Children's Research Foundation, Cincinnati, OH, USA.

    Papers in Europe PMC
  7. 07
    Alessandrì MG9 papers · 2026

    Department of Developmental Neuroscience, IRCCS Stella Maris Foundation, 56128, Pisa, Italy.

    Papers in Europe PMC
  8. 08
    Schulze A9 papers · 2026

    Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, ON, M5G 1X8, Canada.

    Papers in Europe PMC
  9. 09
    Thurm A9 papers · 2026

    National Institute of Mental Health, National Institutes of Health, Bethesda, MD.

    Papers in Europe PMC
  10. 10
    Longo N8 papers · 2026

    Department of Pathology, University of Utah, ARUP Laboratories, Salt Lake City, UT, USA; Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

3

interventional trials for this specific condition

3 interventional trials matched this specific condition name; 2 currently recruiting in our sample.

Data as of 11 September 2026 · last trial check 28 July 2026

3 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 86.7th percentile).

low confidence · 86.7th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

3 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for X-linked creatine transporter deficiency — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("X-linked creatine transporter deficiency" OR "Creatine transporter deficiency" OR "SLC6A8 deficiency" OR "cerebral creatine deficiency syndrome 1" OR "cerebral creatine deficiency syndrome 1, X-linked recessive" OR "cerebral creatine deficiency syndrome type 1") OR (MESH:"Creatine deficiency, X-linked") OR ("SLC6A8" OR "SLC6A8 syndrome" OR "SLC6A8-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Creatine deficiency, X-linked

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"X-linked creatine transporter deficiency" OR "Creatine transporter deficiency" OR "SLC6A8 deficiency" OR "cerebral creatine deficiency syndrome 1" OR "cerebral creatine deficiency syndrome 1, X-linked recessive" OR "cerebral creatine deficiency syndrome type 1" OR "Creatine deficiency, X-linked"

Interventional trials matched via: phrase, mesh (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 3 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1844) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-27T00:50:11.587Z